TNF and Parkinson disease: In another study with a mouse model of PD, administration of an anti-inflammatory glucagon-like peptide-1 (GLP-1) receptor agonist was found to dampen IL-1α, TNF-α, and C1q levels, as well as the formation of neurotoxic reactive astrocytes [41].